Oxford University’s coronavirus vaccine has started human trials in Japan and will be tested on 250 patients as part of a deal to supply it to the country.
UK drug giant AstraZeneca, which owns the rights to the vaccine, announced today that it is beginning Phase 1/2 clinical trials.
The small-scale trials will be done on 250 patients in multiple facilities across the country.
Phase one and two tests are done on small groups of people to see whether the vaccine causes any serious side effects and whether it appears to provoke the immune system. These generally do not prove that it protects against disease.
AstraZeneca has agreed deals with Japanese pharmaceutical companies Daiichi Sankyo and JCR Pharma, and others, to make and distribute the vaccine there.
These trials will form part of that agreement and add to ongoing tests of jab in countries around the world.
Following an announcement on Tuesday that 30,000 American volunteers were taking part in the final stages of the trial, there are now more than 50,000 people testing out the jab – known as AZD1222 – around the world.
Volunteers have already been injected with the experimental drug in the UK, US, Brazil and South Africa and are being monitored by scientists. Further tests are planned in Russia.
Oxford’s Professor Sarah Gilbert, the brains behind the jab, has said preliminary data from trials in some countries could be expected in the coming weeks.
AstraZeneca’s announcement comes as another vaccine hope – made by the German company CureVac – is entering mass production with its developers confirming they plan to manufacture 100million doses by the end of the year.
Oxford’s coronavirus vaccine, AZD1222, has started human trials in Japan and will be tested on 250 patients (stock photo)
It comes as a German biotech firm announced it is planning to produce 100million doses of its vaccine by the end of the year.
A Curevac investor, Dietmar Hopp, told the Handelsblatt business daily on Friday: ‘We want to make 100 million doses available by the end of the year.’
He added that regulatory approval is expected to come in spring or summer next year but said that ‘limited clearance’ could come this year – meaning that people who work in jobs with higher infection rates could be eligible for the jab before others.
The company’s vaccine is likely to be beaten to the market by a US rival, Moderna, and another German company – BioNtech.
Billionaire Mr Hopp added: ‘We can’t win this race. But we want to win the race to produce the best vaccine and here we have good chances.’
German biotech firm announces it will make 100million vaccine doses by end of year
German biotechnology firm Curevac, which has been developing its own Covid-19 vaccine, has announced it expects it will be able to mass-produce the jab by the end of the year.
A Curevac investor, Dietmar Hopp, told the Handelsblatt business daily on Friday: ‘We want to make 100 million doses available by the end of the year.’
He added that regulatory approval is expected to come in spring or summer next year but said that ‘limited clearance’ could come this year – meaning that people who work in jobs with higher infection rates could be eligible for the jab before others.
The company’s vaccine is likely to be beaten to the market by a US rival, Moderna, and another German company – Biontech.
Billionaire Mr Hopp added: ‘We can’t win this race. But we want to win the race to produce the best vaccine and here we have good chances.’
Curevac, worth $10billion, is just one of a number of firms which are desperately trying to create a successful Covid-19 vaccine by using molecules to carry a genetic code called messenger RNA.
Tesla founder Elon Musk was recently spotted in Germany and visited Curevac this week.
Mr Hopp said that Curevac is looking at expanding its cooperation with Grohman (a subsidiary of Tesla) in developing RNA printers which would help vaccine production.
Advertisement
Curevac, worth $10billion, is just one of a number of firms which are desperately trying to create a successful Covid-19 vaccine by using molecules to carry a genetic code called messenger RNA.
Tesla founder Elon Musk was recently spotted in Germany and visited Curevac this week.
Mr Hopp said that Curevac is looking at expanding its cooperation with Grohman (a subsidiary of Tesla) in developing RNA printers which would help vaccine production.
Cambridge-based AstraZeneca said further trials are planned in Russia where there has been a million cases of coronavirus.
AstraZeneca and Oxford scientists have repeatedly promised to deliver the vaccine to the most vulnerable groups to Covid-19 by the end of the year.
Meanwhile, the British drugmaker on Tuesday struck a £15million deal with Oxford Biomedica to mass-produce the vaccine if it is proven to be effective.
Gene and cell therapy firm Oxford Biomedica will be the sole manufacturer of the vaccine in Britain for 18 months.
AstraZeneca has also struck deals with manufacturers in China, the US, and across Europe as it looks to supply the entire world with the Oxford jab.
Oxford Biomedica says it will receive £15m as a capacity reservation fee, plus as much as £35m to make multiple large-scale batches of the vaccine if it works.
Early trials have shown promising results, with tests showing the vaccine is safe to use in humans and appears to provoke an immune response. But data that proves it protects people is not expected until later this year.
To prove without doubt that it protects people from infection, vaccines need to go through rigorous phase three trials.
In these tests the vaccine is being given to tens of thousands of people in real-world environments to see if it stops them from catching Covid-19 in the community.
The Oxford scientists behind the jab had to move their studies abroad over the summer – to South Africa and Brazil where Covid-19 is still rife – to speed up the trials.
There are not enough people catching the virus in the UK anymore to be able to reliably test whether the jab is working.
Professor Sarah Gilbert, who is leading the Oxford team, is confident the jab could be ready for the most vulnerable people in society by the end of the year.
She announced this week that preliminary data from the phase three trials would be presented to regulators soon.
Professor Sarah Gilbert, who is leading the Oxford team, is confident the jab could be ready for the most vulnerable people in society by the end of the year
WHICH COUNTRIES HAVE ORDERED OXFORD’S VACCINE ALREADY?
UK
The UK is the host of research and development efforts of the vaccine, which has been developed by researchers in Oxford and will be manufactured by AstraZeneca, a company based in Cambridge.
The British Government has ordered 100million doses of the jab and has already started manufacturing them so they’re ready to go if and when clinical trials are successful. The price paid has not been disclosed.
US
The US Government has ordered 100million doses of the vaccine and contributed $1.2billion (£910m) to the research and development of the jab.
European Union (EU)
The European Commission has agreed a deal for 300million doses of the vaccine if its clinical trials work, with the option to buy a further 100million. The deal has been made on behalf of countries in the EU. The amount of money spent is unknown.
Australia
Australia has confirmed it ordered enough doses of the vaccine to give one to its entire population of 25million people. It is not clear how many doses the nation has ordered. The UK – with a population of 66m but an order of 100m – ordered more than it needs.
China
One company in China has agreed a deal with AstraZeneca to make at least 100million doses of the vaccine.
Shenzhen Kangtai Biological Products, based in the city of Shenzhen, will increase capacity to 200m per year by the end of 2021.
Russia
A Russian company, R-Pharm, also has a deal to produce and distribute the vaccine, but it is unclear how many it will make or what it will pay to AstraZeneca.
Brazil
Brazilian officials have set aside $360million (£274m) for at least 100million doses of the vaccine. Brazil is currently in one of the worst Covid-19 crises in the world with more than 3.6million official cases so far and 114,000 deaths.
Advertisement
The team have genetically engineered a virus to look like the coronavirus — to have the same spike proteins on the outside — but be unable to cause any infection inside a person.
This virus, weakened by genetic engineering, is a type of virus called an adenovirus, the same as those which cause common colds, that has been taken from chimpanzees.
UK Health Secretary Matt Hancock says frontline health and care workers, and those at an increased risk of serious disease, including elderly care homes residents, will be first in line to get access to a vaccine.
Over-50s and those with heart and kidney disease will be next, according to Mr Hancock, who said health bosses were also considering fast-tracking access for people from BAME backgrounds, who are disproportionately affected by Covid-19.
It’s more likely the average person will get their hands on a Covid-19 sometime in early 2021, according to the UK’s vaccine tsar, Kate Bingham.
Mass-manufacturing is already under way, however, so that the vaccine can be produced as quickly as possible.
AstraZeneca claims it can manufacture two billion doses by summer 2021. The US has already ordered 300million doses and the UK has pre-purchased 100million.
It emerged last week that Number 10 is drawing up emergency plans now in case of a scientific breakthrough before Christmas, officials said.
The new rules being drafted will not shortcut the path a vaccine must take before it is approved for human use, and rigorous clinical trials must still be completed.
It is intended, instead, to speed up the approval process by giving the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) the power to issue a ‘temporary authorisation’ without waiting for the jab to be fully licensed by Europe.
Rules during the Brexit transition period – which doesn’t end until 2021 – mean any new medicine for coronavirus must be licensed by the European Medicines Agency.
But the new rule – for which officials are holding a three-week consultation – would mean that if scientists prove their vaccine works and is safe, the MHRA could approve it and get it used in Britain before it’s licensed by the European Union.
This will not cut short safety trials or any of the scientific work but will mean less paperwork has to be done before the jab can be used.
The rules are being drafted now in case a working vaccine is found before the end of the year, while the Brexit transition period is still going.
Drug manufacturers are so hopeful that their jabs will work that they are already manufacturing millions of them without knowing whether they will be used.
As well as speeding up the process of getting it from labs to patients, the British Government is planning to speed up the vaccination programme once it starts.
It will do this by training huge numbers of staff to give out the vaccines so there can be a constant flow of jabs being administered.
More doctors and nurses will be given the relevant training and health workers in other parts of the NHS may also be trained up.
Student doctors and nurses, and staff such as midwives, paramedics and physiotherapists could be among the newly trained staff.
There are around 1.1million people working in the NHS and officials say ‘no options are off the table’ in who they could train up.
Everyone who is included in the programme will go through a ‘robust training programme’, the Department of Health said.
WHICH VACCINES HAVE THE UK SECURED DEALS FOR?
1. GlaxoSmithKline and Sanofi Pasteur: 60million doses
The Government revealed on July 29 it had signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur
If the vaccine proves successful, the UK could begin to vaccinate priority groups, such as frontline health and social care workers and those at increased risk from coronavirus, as early as the first half of next year, the Department for Business, Energy & Industrial Strategy (BEIS) said.
Human clinical studies of the vaccine will begin in September followed by a phase 3 study in December.
The vaccine is based on the existing technology used to produce Sanofi’s seasonal flu vaccine. Genetic material from the surface protein of the SARS-CoV-2 virus is inserted into insect cells – the basis of Sanofi’s influenza product – and then injected to provoke an immune response in a human patient.
2. AstraZeneca (manufacturing University of Oxford’s): 100million
AstraZeneca, which is working in partnership with Oxford University, is already manufacturing the experimental vaccine after a deal was struck on May 17.
Professor Sarah Gilbert, who is leading the Oxford team, is confident the jab could be ready for the most vulnerable people by the end of the year.
Her comments came after the results from the first phase, published in The Lancet on July 20, showed promise.
The team have genetically engineered a virus to look like the coronavirus – to have the same spike proteins on the outside – but be unable to cause any infection inside a person. This virus, weakened by genetic engineering, is a type of virus called an adenovirus, the same as those which cause common colds, that has been taken from chimpanzees.
3. BioNTech/Pfizer: 30million
US drug giant Pfizer – most famous for making Viagra – and German firm BioNTech were revealed to have secured a deal with the UK Government on July 20.
It reported positive results from the ongoing phase 2/3 clinical trial of one called BNT162b1 on July 1. The company is still running phase 2 trials at the moment.
Pfizer’s vaccine is one called an mRNA vaccine, which do not directly inject bits of the virus into the body but send genetic material.
mRNA vaccines programme the body to produce parts of the virus itself by injecting the body with a molecule that tells disease-fighting cells what to build. The immune system then learns how to fight it.
4. Valneva: 60million
The Government has given Valneva — whose vaccine is understood to be in the preclinical stages of development — an undisclosed amount of money to expand its factory in Livingston, Scotland.
While the Government revealed a 60million dose deal on July 20, the company said it had reached agreement in principle with the UK government to provide up to 100million doses.
Valneva’s jab is an inactivated whole virus vaccine, meaning it injects a damaged version of the coronavirus itself into the body.
The virus has been destroyed in a way that makes it unable to cause infection, but the body still recognises it as a dangerous intruder and therefore mounts an immune response which it can remember in case of a real Covid-19 infection.
5. Janssen (Johnson & Johnson): 30million
The Government has agreed to buy 30million doses of a vaccine made by Janssen if it works.
Officials have agreed to help the company in its development of the jab by part-funding a global clinical trial. The first in-human trials of Janssen’s jab began in mid-July and are being done on adults over the age of 18 in the US and Belgium.
The jab is named Ad26.COV2-S, recombinant, and is a type of jab called a viral vector recombinant vaccine.
Proteins that appear on the outside of the coronavirus are reproduced in a lab and then injected into the body to stimulate an immune reaction.
The ‘Ad’ part of the vaccine’s name means it works using an adenovirus – a virus best known for causing the common cold – as a vehicle to transport the coronavirus genetics into the body.
6. Novavax: 60million
Britain has ordered 60million doses of a vaccine being developed by the US-based company Novavax. It will help to fund late-stage clinical trials in the UK and also boost plans to manufacture the vaccine in Britain.
Novavax’s jab, named NVX-CoV2373, showed positive results in early clinical trials.
It produced an immune response in 100 per cent of people who received it, the company said, and was safe and ‘generally well-tolerated’.
Novavax’s candidate is also a recombinant vaccine and transports the spike proteins found on the outside of the coronavirus into the body in order to provoke the immune system.
7. Imperial College London: Unknown quantity
Imperial College London scientists are working on Britain’s second home-grown hope for a jab. The candidate is slightly behind Oxford’s vaccine in terms of its progress through clinical trials, but is still a major player.
The UK Government is understood to have agreed to buy the vaccine if it works but details of a deal have not yet been publicised.
Imperial’s jab is currently in second-phase human trials after early tests showed it appeared to be safe.
Imperial College London will try to deliver genetic material (RNA) from the coronavirus which programs cells inside the patient’s body to recreate the spike proteins. It will transport the RNA inside liquid droplets injected into the bloodstream.
Advertisement
Link nguồn : https://www.dailymail.co.uk/news/article-8697471/Oxfords-coronavirus-vaccine-enters-human-trials-Japan.html
